Standing Order
Amgen Inc.

Dashboard

Amgen Inc.

AMGNNASDAQ

For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.

Universal block

Live market data + trailing fundamentals.

Market cap$203B
Price$376.0452w $271.18 – $388.16
Conviction5/ 5
Revenue (TTM)$37.2B
Revenue growth YoY+9.1%
P/E (trailing)26.0
Gross margin71.5%
Operating margin31.6%
Net margin20.9%
52w price change+30.4%
Next earningsAug 4, 2026

Recent events

Material filings, federal awards, and regulatory activity. Impact is scored against market cap.

  • Jul 16
    RegulatoryFDA

    FDA supplemental submission (SUPPL-5202) for NEUPOGEN (BLA103353) filed 2026-07-16.

  • Jun 23
    RegulatoryFDA

    FDA supplemental submission (SUPPL-224) for PROLIA (BLA125320) with status date 2026-06-23.

  • Jun 23
    RegulatoryFDA

    FDA supplemental submission (SUPPL-225) for PROLIA (BLA125320) filed 2026-06-23.

  • Jun 3
    Trial initiationClinicalTrials.gov

    Phase 1/2 TINI 2 trial (NCT05848687) for infant ALL recruiting

  • Jun 2
    DealFederal award

    Amgen awarded $7.29M HHS contract for Nplate kit development incl. ARS indications

    $7M
  • May 29
    Trial initiationClinicalTrials.gov

    Amgen initiates Phase 1 trial (NCT07037758) of Tarlatamab + AB248 in extensive-stage small cell lung cancer; status recruiting.

  • May 21
    OtherSEC

    SEC Form 4 filing reporting change in beneficial ownership.

  • May 21
    OtherSEC

    SEC Form 4 insider ownership filing

  • May 21
    OtherSEC

    Amgen filed SEC Form 4 reporting change in beneficial ownership by insider.

  • May 21
    OtherSEC

    Amgen files SEC Form 4 reporting change in beneficial ownership.

  • May 21
    OtherSEC

    Form 4 insider transaction filing

  • May 21
    OtherSEC

    SEC Form 4 filing on changes in beneficial ownership.

  • May 21
    OtherSEC

    SEC Form 4 insider ownership change filing

  • May 21
    OtherSEC

    SEC Form 4 filing for change in beneficial ownership by insider.

  • May 21
    OtherSEC

    SEC Form 4 insider beneficial ownership filing

  • May 21
    OtherSEC

    Amgen Form 4 insider beneficial ownership change filing.

  • May 21
    OtherSEC

    SEC Form 4 insider transaction filing.

  • May 20
    OtherSEC

    Amgen 8-K item 5.07 filed disclosing results of matters submitted to shareholder vote.

  • May 19
    LeadershipSEC

    Amgen filed 8-K (item 5.02) on officer or director changes.

  • May 11
    OtherSEC

    SEC Form 4 insider beneficial ownership filing.

Not financial advice — research and opinion only. Disclosures